Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 234 items for :

  • "Graves’" x
Clear All
Birgitta Johansson Department of Clinical Neuroscience, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden

Search for other papers by Birgitta Johansson in
Google Scholar
PubMed Close
,
Mats Holmberg ANOVA, Karolinska University Hospital, Norra Stationsgatan 69, Stockholm, Sweden
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden

Search for other papers by Mats Holmberg in
Google Scholar
PubMed Close
,
Simon Skau Department of Clinical Neuroscience, Sahlgrenska Academy, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
Department of Pedagogical, Curricular and Professional Studies, Faculty of Education, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Simon Skau in
Google Scholar
PubMed Close
,
Helge Malmgren Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Search for other papers by Helge Malmgren in
Google Scholar
PubMed Close
, and
Helena Filipsson Nyström Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden

Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed Close

Introduction Untreated hyperthyroid patients with Graves’ disease (GD, autoimmune hyperthyroidism) often report fatigue, cognitive problems, and emotional distress. Once the patients are regarded as clinically recovered and euthyroid, the

Article Type:
Research Article
Collections:
Hyperthyroidism and thyrotoxicosis
DOI:
https://doi.org/10.1530/ETJ-23-0040
Volume/Issue:
Volume 12: Issue 4
Open access
Luigi Bartalena Department of Clinical and Experimental Medicine, University of Insubria, Endocrine Unit, Ospedale di Circolo, Varese, Italy

Search for other papers by Luigi Bartalena in
Google Scholar
PubMed Close
,
Lelio Baldeschi Department of Ophthalmology, Hospital Saint Luc, Catholic University of Louvain, Brussels, Belgium

Search for other papers by Lelio Baldeschi in
Google Scholar
PubMed Close
,
Kostas Boboridis Ophthalmology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece

Search for other papers by Kostas Boboridis in
Google Scholar
PubMed Close
,
Anja Eckstein Zentrum für Augenheilkunde, Universitätsklinikum Essen, Essen

Search for other papers by Anja Eckstein in
Google Scholar
PubMed Close
,
George J. Kahaly Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by George J. Kahaly in
Google Scholar
PubMed Close
,
Claudio Marcocci Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close
,
Petros Perros Department of Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Search for other papers by Petros Perros in
Google Scholar
PubMed Close
,
Mario Salvi Graves' Orbitopathy Center, Endocrinology, Fondazione Ca' Granda IRCCS, University of Milan, Milan, Italy

Search for other papers by Mario Salvi in
Google Scholar
PubMed Close
, and
Wilmar M. Wiersinga Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Search for other papers by Wilmar M. Wiersinga in
Google Scholar
PubMed Close

Introduction In 2008, EUGOGO published a consensus statement on the management of Graves' orbitopathy (GO) simultaneously in the European Journal of Endocrinology and in Thyroid [ 1 , 2 ]. The statement was received very well [ 3 ] and has

Article Type:
Guideline
DOI:
https://doi.org/10.1159/000443828
Volume/Issue:
Volume 5: Issue 1
Free access
Giulia Masetti Thyroid Research Group, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Computational Metagenomics, CIBIO Department, University of Trento, Trento, Italy

Search for other papers by Giulia Masetti in
Google Scholar
PubMed Close
and
Marian Ludgate Thyroid Research Group, Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom

Search for other papers by Marian Ludgate in
Google Scholar
PubMed Close

Introduction As already described in the other excellent contributions to this collection, Graves’ disease (GD) is an autoimmune condition in which thyroid-stimulating antibodies (TSAb) target the thyroid-stimulating hormone receptor (TSHR

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000512255
Volume/Issue:
Volume 9: Issue 1_Suppl
Free access
Earn H. Gan Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Earn H. Gan in
Google Scholar
PubMed Close
,
Anna L. Mitchell Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed Close
,
Ruth Plummer Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Ruth Plummer in
Google Scholar
PubMed Close
,
Simon Pearce Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Simon Pearce in
Google Scholar
PubMed Close
, and
Petros Perros Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom

Search for other papers by Petros Perros in
Google Scholar
PubMed Close

What Is Known about This Topic? Anti-CTLA-4 immunotherapy used in cancer treatment can cause thyroiditis and Graves disease. What Does This Case Report Add? Transient thyroiditis and Graves disease usually take place within

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000464285
Volume/Issue:
Volume 6: Issue 3
Free access
Claudio Marcocci Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close
,
Marenza Leo Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

Search for other papers by Marenza Leo in
Google Scholar
PubMed Close
, and
Maria Antonietta Altea Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

Search for other papers by Maria Antonietta Altea in
Google Scholar
PubMed Close

, elevated intracellular ATP consumption, and increased ROS production [ 5 , 6 ]. Moreover, there is evidence supporting a role of oxidative processes in the genesis of Graves’ disease (GD) [ 7 ], hyperthyroidism-induced damage such as thyrotoxic myopathy and

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000337976
Volume/Issue:
Volume 1: Issue 2
Free access
Giulia Lanzolla Endocrinology Unit II, Department of Clinical and Experimental Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Giulia Lanzolla in
Google Scholar
PubMed Close
,
Claudio Marcocci Endocrinology Unit II, Department of Clinical and Experimental Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close
, and
Michele Marinò Endocrinology Unit II, Department of Clinical and Experimental Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Michele Marinò in
Google Scholar
PubMed Close

Introduction Graves disease (GD) is a common autoimmune disease, with a prevalence of ∼1% [ 1 ]. Although GD affects primarily the thyroid, extrathyroidal manifestations, i.e., Graves orbitopathy (GO), pretibial myxoedema, and acropachy [ 2

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000509615
Volume/Issue:
Volume 9: Issue 1_Suppl
Free access
Mats Holmberg ANOVA, Karolinska University Hospital, Norra Stationsgatan 69, Stockholm, Sweden
Institute of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden

Search for other papers by Mats Holmberg in
Google Scholar
PubMed Close
,
Helge Malmgren Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

Search for other papers by Helge Malmgren in
Google Scholar
PubMed Close
,
Peter F Berglund Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

Search for other papers by Peter F Berglund in
Google Scholar
PubMed Close
,
Birgitta Johansson Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

Search for other papers by Birgitta Johansson in
Google Scholar
PubMed Close
, and
Helena Filipsson Nyström Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden
Gothenburg Centre for Person Centred-Care (GPCC), Göteborg, Sweden

Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed Close

Introduction Mental symptoms and reduced quality of life (QoL) are common brain-derived problems in untreated Graves’ hyperthyroidism ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ). In a 2006 review (meta

Article Type:
Research Article
Collections:
Hyperthyroidism and thyrotoxicosis
DOI:
https://doi.org/10.1530/ETJ-23-0247
Volume/Issue:
Volume 13: Issue 1
Open access
John H. Lazarus Centre for Endocrine and Diabetes Sciences, Cardiff University, Cardiff, UK

Search for other papers by John H. Lazarus in
Google Scholar
PubMed Close

gestation. In contrast, TSH receptor antibodies have a prevalence of around 0.01%, but neonatal hyperthyroidism occurs in 30% of TSH receptor antibody-positive women [ 2 ]. Course of Graves’ Disease during Pregnancy Deterioration in the clinical

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000336102
Volume/Issue:
Volume 1: Issue 1
Free access
Hiroki Kobayashi Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Hiroki Kobayashi in
Google Scholar
PubMed Close
,
Akira Haketa Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Akira Haketa in
Google Scholar
PubMed Close
,
Masanori Abe Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Masanori Abe in
Google Scholar
PubMed Close
,
Kazunobu Tahira Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Kazunobu Tahira in
Google Scholar
PubMed Close
,
Yoshinari Hatanaka Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Yoshinari Hatanaka in
Google Scholar
PubMed Close
,
Sho Tanaka Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Sho Tanaka in
Google Scholar
PubMed Close
,
Takahiro Ueno Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Takahiro Ueno in
Google Scholar
PubMed Close
, and
Masayoshi Soma Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for other papers by Masayoshi Soma in
Google Scholar
PubMed Close

thyrotoxicosis [ 4 ]. However, some reports have demonstrated other causes of VF [ 5 , 6 ]. We report here a case of Graves' disease with VF as the result of thyrotoxicosis and review the literature on VF associated with thyrotoxicosis. This case suggests that

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000437225
Volume/Issue:
Volume 4: Issue 3
Free access
Elena Sabini Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Elena Sabini in
Google Scholar
PubMed Close
,
Ilaria Ionni Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Ilaria Ionni in
Google Scholar
PubMed Close
,
Roberto Rocchi Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Roberto Rocchi in
Google Scholar
PubMed Close
,
Paolo Vitti Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Paolo Vitti in
Google Scholar
PubMed Close
,
Claudio Marcocci Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Claudio Marcocci in
Google Scholar
PubMed Close
, and
Michele Marinò Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa and University Hospital of Pisa, Pisa, Italy

Search for other papers by Michele Marinò in
Google Scholar
PubMed Close

What Is Known about This Topic? Graves’ orbitopathy is believed to be the consequence of autoimmunity against antigens present both in the thyroid and in orbital tissues. Massive release of thyroid antigens causes the appearance or

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000479629
Volume/Issue:
Volume 7: Issue 1
Free access